Eli Lilly Gains Ground in Weight-Loss Drug Race with Trial Results

Eli Lilly's oral drug shows superior weight loss and blood sugar control vs. Novo Nordisk's Rybelsus in Phase 3, but with higher side effects. FDA decision on obesity use expected soon.

The battle for dominance in the highly profitable obesity and diabetes treatment market has intensified. Newly released Phase 3 trial data from Eli Lilly presents a significant challenge to its main competitor, Novo Nordisk. While the oral candidate orforglipron demonstrated superior efficacy, the detailed results also highlight specific patient challenges.

Efficacy Data Shows Strong Advantage

Findings from the "ACHIEVE-3" study, published Thursday in The Lancet, pit Eli Lilly's orforglipron directly against Novo Nordisk's established oral semaglutid, marketed as Rybelsus. The data delivers a clear message in favor of the U.S. pharmaceutical firm.

Participants receiving the highest dose of the Lilly drug experienced an average weight reduction of 19.7 pounds (approximately 9 kg). In contrast, the group treated with the highest dose of the rival product lost an average of only 11.0 pounds (about 5 kg). Orforglipron also significantly outperformed its competitor on the study's primary goal of lowering A1C blood sugar levels, achieving a reduction of 2.2 percentage points versus 1.4 percentage points.

Convenience and Tolerability Profile

A potential market advantage for Eli Lilly lies in administration. Orforglipron offers greater flexibility than Rybelsus, which has strict instructions requiring administration on an empty stomach. The Lilly tablet can be taken at any time of day without restrictions regarding food or water intake—a crucial factor for real-world patient adherence.

However, the robust efficacy came with a trade-off. The treatment was associated with a higher incidence of side effects. Discontinuation rates due to tolerability issues were between 9% and 10% for orforglipron patients. This rate was notably lower, at 4% to 5%, for the comparator group.

Strategic Timing and Regulatory Path

The positive clinical news arrives at a pivotal moment for Eli Lilly. Its shares recently traded at 866.00 euros, reflecting a year-to-date decline of roughly 6%. Success in its drug pipeline is essential to bolstering investor confidence in the company's long-term growth trajectory.

A key regulatory milestone is imminent. The company anticipates a decision from the U.S. Food and Drug Administration (FDA) on the use of orforglipron for obesity in the second quarter. Securing approval would substantially strengthen Eli Lilly's position within its duopoly with Novo Nordisk, expanding its portfolio with a potent and convenient new treatment option.